As the global pharmaceutical landscape continues to evolve following the landmark UK–US agreement, explore what this means for our customers in today’s environment. Six months on, tariff policy, supply chain dynamics, and global trade conditions have continued to shift, reinforcing the importance of strategic flexibility and resilient operating models.
What exactly is the agreement?
At its core, the UK–US pharmaceutical arrangement continues to provide:
- 0% tariff on UK pharmaceutical exports to the US until at least January 2029
- Coverage across medicines, APIs, and medical technologies
- A broader framework linking tariff access to pricing alignment and supply chain cooperation
The agreement strengthens the resilience of the interconnected UK-US pharmaceutical supply chain, which is critical for the movement of medicines, APIs, raw materials and technology. At this point in time, the UK is the only country with guaranteed tariff-free access to the US market for these products. This reduces reliance solely on other markets and has the potential to positively impact our customer’s projects, providing increased options across geographic regions.
What has changed in the macro environment since the UK-US trade announcement?
Since early 2026, several important shifts have reshaped the global operating context meaning that tariffs are now a structural feature of trade and not a temporary disruption. Governments are increasingly using tariffs as industrial policy tools to reshore manufacturing and control pricing, the era of near-frictionless pharmaceutical trade has fundamentally shifted. Supply chains are fragmenting and regionalising with over 80% of supply chain leaders reporting active restructuring due to tariff pressure .
Nearshoring and dual sourcing are becoming standard practices as geoeconomic change management has become a top priority and global risk frameworks now rank trade disruption and tariff volatility among the most significant business risks .
What does this mean for our customers?
Immediate cost efficiency with greater strategic value: sourcing from UK manufacturing sites continues to provide tariff-free access to the US market, but today this advantage is amplified by rising tariffs elsewhere. In an environment where non-aligned routes may face double-digit tariff exposure, and landed cost volatility is increasing, the UK offers not just cost parity but cost predictability and protection.
A resilient ‘safe harbour’: now an increasing necessity in a volatile global system and to that point the UK–US corridor provides:
- Reduced exposure to escalating US tariff regimes
- Alignment with Western regulatory and policy frameworks
- A more stable pathway for critical supply chains
For many of the other organisations we partner with, this has shifted from being an optional optimisation to a core risk mitigation strategy.
The UK continues to offer pharmaceutical organisations:
- Accelerated development and speed to market
- Rapid clinical development timelines
- Strong integration of digital tools and regulatory frameworks
- Safe data and IP monitoring policies
In the current environment, speed, control and safety is no longer just a competitive advantage, it is a way to reduce exposure to policy and cost uncertainty over time.
The tariff opportunity creates a further platform for supply chain strategy in drug development, not just sourcing. The changing trade environment means procurement decisions cannot be made purely on unit cost, instead, organisations much review the total landed cost and how stable it is, a multi-region supply strategy for continuity and how flexible the partners they choose to work with are so they can quickly adapt to policy changes. The UK–US corridor provides a foundation for longer-term strategic planning in getting medicines to market, rather than short-term optimisation.
How will Sterling continue to leverage these changes?
Longer term as the project develops, we help to design resilient, future-ready supply chains, working with our customers to build cross-border strategies that anticipate tariff evolution, create optionality across manufacturing locations and align early development decisions with long-term commercial resilience.
Utilising global resources more effectively: This provides us with the continued opportunity to integrate projects across our network to use the most appropriate experts, equipment and capacity available to meet the requirements of customers.
Use our collective power through our Extended Bench™ model: Global integration of our internal networks provides scientific and operational resources when and where needed, eliminating tech transfers, reducing reliance on fixed site strategies and preserving timelines and cost efficiency.
Develop stable and secure supply chain strategies with customers: By helping customers develop robust cross-border manufacturing strategies, Sterling can add value from the earliest stages of development through scale-up, launch and long-term commercial supply. This end-to-end approach enhances geographic and supply chain resilience, creates greater operational flexibility, and enables proactive responses to evolving tariff and trade environments. Where appropriate, projects can be aligned to the most advantageous manufacturing location, supporting both commercial performance and long-term supply continuity
Continue to support industry innovation: We will continue to invest in the latest technologies and in improved capacity to aid the development of next generation medicines. This includes working with peers in industry on groundbreaking innovations and research to develop the global market.
Why is Sterling well placed to do this?
Sterling is a specialist Partnership Development and Manufacturing Organisation (PDMO®) with a fully integrated global footprint across the UK, US, and Europe and more than 50 years’ experience. This provides us with a deep expertise across the full product lifecycle and a proven ability to navigate complex regulatory and supply chain environments, our view is that in today’s environment, this global integration is not just a capability, it is a strategic enabler.
The UK–US agreement continues to provide a clear advantage, but its significance has grown in the context of the evolving global trade landscape. What began as a tariff benefit has become a strategic supply corridor in a fragmented global system and a risk mitigation tool against escalating tariff regimes when deployed effectively.
This creates a platform for resilient, future-ready pharmaceutical supply chains providing continued access to innovative medicines to the patients we serve. For our partners, it provides a reliable pathway through increasing global complexity.
At Sterling, we remain focused on helping our customers translate these market shifts into practical, competitive advantage.
